Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06608329

A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects

A Randomized, Open-label, Crossover Study to Evaluate Relative Bioavailability, and Food Effect of HDM1002 in Healthy Subjects

Status
Not Yet Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
33 (estimated)
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The main purpose of this study is to evaluate the effect of formulation on relative bioavailability of HDM1002, and the food effect on pharmacokinetics of HDM1002.

Conditions

Interventions

TypeNameDescription
DRUGHDM1002Single dose, administered orally. The study is a randomized, open-label, single dose, 3-period, 3 sequence, crossover design.

Timeline

Start date
2024-10-01
Primary completion
2024-11-01
Completion
2024-12-01
First posted
2024-09-23
Last updated
2024-09-23

Locations

1 site across 1 country: China

Regulatory

Source: ClinicalTrials.gov record NCT06608329. Inclusion in this directory is not an endorsement.